In addition, tumor-associated DCs (TADCs) in multiple tumors express high levels of Tim-3 [62,63,64], and the effects of anti-Tim-3 antibody treatment in improving the anti-tumor efficacy of chemotherapy and DC vaccines are dependent on DCs [62,65]. This evidence concerns the gene HAVCR2 and neoplasm.